Swiss pharma giant Roche’s (ROG: SIX) Vabysmo (faricimab) is in the spotlight following its promising first-quarter 2024 sales figures.
Vabysmo, which gained US Food and Drug Administration (FDA) approval in January 2022, had sales of $927 million during the quarter.
The vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 inhibitor therapy, is indicated for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze